{"id":95770,"date":"2023-03-17T13:30:00","date_gmt":"2023-03-17T08:00:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=95770"},"modified":"2023-03-17T14:29:06","modified_gmt":"2023-03-17T08:59:06","slug":"pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/","title":{"rendered":"Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1860320883\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>With a market capitalization of \u20b9 15331 crores, Ajanta Pharma is a small-cap pharmaceutical company that is engaged in the development, manufacturing and marketing of speciality pharmaceutical quality finished dosages. Its shares were trading at \u20b9 1195 levels on Friday.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-4213808778\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>The company\u2019s board has approved the proposal of a buy-back of 22,10,500 fully paid-up equity shares having a face value of \u20b9 2 each at \u20b9 1425 apiece. This means that they will be buying the shares at a premium of \u20b9 230 per share. This takes the value to approximately \u20b9 315 crores.&nbsp;<\/p><p>The board has further considered and approved the record date as Friday, March 24, 2023, for the purpose of determining the entitlement and names of equity shareholders who shall be participating in the buyback.&nbsp;<\/p><p>Ajanta Pharma has an ideal return on equity of 22.77% and an ideal debt-to-equity ratio of 0.01. Its shares were trading at a price-to-earnings ratio (P\/E) of 24.92, which is slightly lower than the industry P\/E of 25.86, indicating that the stock might be undervalued as compared to its peers. Its promoters hold a 66.11% stake in it.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-2118815769\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p><strong>Written by Simran Bafna&nbsp;<\/strong><\/p><p>Source Source<\/p><div class=\"trade-after-content\" id=\"trade-2826993646\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>With a market capitalization of \u20b9 15331 crores, Ajanta Pharma is a small-cap pharmaceutical company that is engaged in the development, manufacturing and marketing of speciality pharmaceutical quality finished dosages. Its shares were trading at \u20b9 1195 levels on Friday.&nbsp; The company\u2019s board has approved the proposal of a buy-back of 22,10,500 fully paid-up equity [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":49884,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[4865,31],"tags":[],"class_list":["post-95770","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0 - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The company has an ideal return on equity of 22.77% and an ideal debt-to-equity ratio of 0.01. Its shares were trading at a price-to-earnings ratio (P\/E) of 24.92, which is slightly lower than the industry P\/E of 25.86, indicating that the stock might be undervalued as compared to its peers. Its promoters hold a 66.11% stake in it.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-\u20b9-230-check-the-details\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0\" \/>\n<meta property=\"og:description\" content=\"The company has an ideal return on equity of 22.77% and an ideal debt-to-equity ratio of 0.01. Its shares were trading at a price-to-earnings ratio (P\/E) of 24.92, which is slightly lower than the industry P\/E of 25.86, indicating that the stock might be undervalued as compared to its peers. Its promoters hold a 66.11% stake in it.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-\u20b9-230-check-the-details\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-17T08:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-17T08:59:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/\",\"name\":\"Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0 - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"datePublished\":\"2023-03-17T08:00:00+00:00\",\"dateModified\":\"2023-03-17T08:59:06+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The company has an ideal return on equity of 22.77% and an ideal debt-to-equity ratio of 0.01. Its shares were trading at a price-to-earnings ratio (P\/E) of 24.92, which is slightly lower than the industry P\/E of 25.86, indicating that the stock might be undervalued as compared to its peers. Its promoters hold a 66.11% stake in it.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0 - Trade Brains Features","description":"The company has an ideal return on equity of 22.77% and an ideal debt-to-equity ratio of 0.01. Its shares were trading at a price-to-earnings ratio (P\/E) of 24.92, which is slightly lower than the industry P\/E of 25.86, indicating that the stock might be undervalued as compared to its peers. Its promoters hold a 66.11% stake in it.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-\u20b9-230-check-the-details\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0","og_description":"The company has an ideal return on equity of 22.77% and an ideal debt-to-equity ratio of 0.01. Its shares were trading at a price-to-earnings ratio (P\/E) of 24.92, which is slightly lower than the industry P\/E of 25.86, indicating that the stock might be undervalued as compared to its peers. Its promoters hold a 66.11% stake in it.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-\u20b9-230-check-the-details\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2023-03-17T08:00:00+00:00","article_modified_time":"2023-03-17T08:59:06+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_image":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/","name":"Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0 - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","datePublished":"2023-03-17T08:00:00+00:00","dateModified":"2023-03-17T08:59:06+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The company has an ideal return on equity of 22.77% and an ideal debt-to-equity ratio of 0.01. Its shares were trading at a price-to-earnings ratio (P\/E) of 24.92, which is slightly lower than the industry P\/E of 25.86, indicating that the stock might be undervalued as compared to its peers. Its promoters hold a 66.11% stake in it.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-announces-buyback-of-share-at-a-premium-of-%e2%82%b9-230-check-the-details\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock announces buyback of share at a premium of \u20b9 230; Check the details\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/95770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=95770"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/95770\/revisions"}],"predecessor-version":[{"id":95771,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/95770\/revisions\/95771"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/49884"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=95770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=95770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=95770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}